These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26378740)

  • 1. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
    Rombouts FJ; Tresadern G; Delgado O; Martínez-Lamenca C; Van Gool M; García-Molina A; Alonso de Diego SA; Oehlrich D; Prokopcova H; Alonso JM; Austin N; Borghys H; Van Brandt S; Surkyn M; De Cleyn M; Vos A; Alexander R; Macdonald G; Moechars D; Gijsen H; Trabanco AA
    J Med Chem; 2015 Oct; 58(20):8216-35. PubMed ID: 26378740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
    Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R
    J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of amidine-based brain penetrant BACE1 inhibitors.
    Oehlrich D; Prokopcova H; Gijsen HJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    Dineen TA; Weiss MM; Williamson T; Acton P; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dunn RT; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; San Miguel T; Sickmier EA; Vargas HM; Wahl RC; Wen PH; Whittington DA; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
    J Med Chem; 2012 Nov; 55(21):9025-44. PubMed ID: 22468684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284).
    Gilbert EJ
    Expert Opin Ther Pat; 2013 Aug; 23(8):1069-73. PubMed ID: 23837729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
    Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
    Machauer R; Lueoend R; Hurth K; Veenstra SJ; Rueeger H; Voegtle M; Tintelnot-Blomley M; Rondeau JM; Jacobson LH; Laue G; Beltz K; Neumann U
    J Med Chem; 2021 Oct; 64(20):15262-15279. PubMed ID: 34648711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
    Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.